Compare AbbVie Inc (ABBV) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Firy Inc. — how do they compare? AbbVie Inc trades at $253.18 (market cap $449.91B), while Firy Inc. trades at $8.92 (market cap $143.59M). The key difference: AbbVie Inc is far larger — about 3133.3× Firy Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| ABBV | FIRY | |
|---|---|---|
Market Cap | $449.91B | $143.59M |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $12.45 |
52-Week Low | $184.85 | $2.28 |
Enterprise Value | $513.38B | $87.26M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
FIRY, formerly Skillz Inc., trades at $9.20, down 5.54% today, amid a recent rebranding and mixed quarterly results. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; the company's cost structure and profitability challenges pose significant risks, offset by potential from legal victories and strategic shifts. Analysts are mostly neutral, with 60% hold ratings. Investors should weigh the high execution risk against any turnaround prospects in the competitive mobile gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
